Exponent doubles down on proven growth model with £900m fund

Exponent has secured £900 million for its fifth fund, reinforcing its commitment to acquiring and scaling well-established corporate, family, and founder-led businesses. The firm, now based in Dublin, has already injected over €1 billion into Irish enterprises and is accelerating its footprint across sectors—from pharmaceuticals and private healthcare to data centre design and high-voltage engineering.

With recent deals including Chanelle Pharmaceuticals, Kingsbridge Healthcare, and Ethos Engineering, Exponent continues to back assets where it sees clear potential to double profits through revenue-driven growth. Its strategy, tested and refined over two decades, appeals to owners seeking both capital and operational depth—without diluting legacy or control.

The firm’s confident raise of Fund V signals enduring investor trust in its disciplined, subsector-specific approach to value creation. Want the full story? Read the complete article here.